Dossier
Crinetics shares
Coverage of Crinetics shares in the Nexus archive.
- STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion, gaining access to its drug Palsonify for acromegaly and other drug candidates. The acquisition, valued at $85 per share, caused Crinetics' shares to rise 101% in after-hours trading.